2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment

BACKGROUND: Darunavir (DRV) is a well-tolerated, potent protease inhibitor used once-daily in patients with no DRV resistance-associated mutations (RAMs) and twice-daily in those with DRV RAMs. Treatment guidelines encourage use of once-daily regimens to optimize patient adherence, convenience and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolle, Charlotte-Paige M, Marquez, Omar, Nguyen, Vu, Hinestrosa, Federico, DeJesus, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810351/
http://dx.doi.org/10.1093/ofid/ofz360.2160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810351/
http://dx.doi.org/10.1093/ofid/ofz360.2160

Ejemplares similares